EP2485809A2 - Kosmetische oder dermatologische zubereitungen mit kombinationen aus 4-n-butylresorcin und einem oder mehreren sulfiten, insbesondere hydrogensulfiten und/oder disulfiten - Google Patents
Kosmetische oder dermatologische zubereitungen mit kombinationen aus 4-n-butylresorcin und einem oder mehreren sulfiten, insbesondere hydrogensulfiten und/oder disulfitenInfo
- Publication number
- EP2485809A2 EP2485809A2 EP10737499A EP10737499A EP2485809A2 EP 2485809 A2 EP2485809 A2 EP 2485809A2 EP 10737499 A EP10737499 A EP 10737499A EP 10737499 A EP10737499 A EP 10737499A EP 2485809 A2 EP2485809 A2 EP 2485809A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- cosmetic
- sulfites
- butylresorcinol
- preparations
- disulfites
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Definitions
- the present invention relates to cosmetic or dermatological preparations with combinations of 4-n-butylresorcinol and one or more disulfites.
- melanocytes responsible for the pigmentation of the skin are the melanocytes, which are found in the lowest layer of the epidermis, the stratum basale, in addition to the basal cells - depending on the skin type either isolated or more or less frequently occurring - pigment-forming cells.
- Melanocytes contain as characteristic cell organelles melanosomes, in which the melanin is formed. Among other things, upon excitation by UV radiation melanin is increasingly formed. This is transported via the living layers of the epidermis (keratinocytes) ultimately in the horny layer (corneocytes) and causes a more or less pronounced brownish to brown-black skin color.
- DHICA and DHI melanin are produced via the common intermediates dopaquinone and dopachrome. The latter is reacted, sometimes involving other enzymes, either in indole-5,6-quinone carboxylic acid or in indole-5,6-quinone, resulting in the two mentioned eumelanins.
- CONFIRMATION COPY Enzymes by a specific transcription factor microphthalmia-associated transcription factor, MITF.
- MITF microphthalmia-associated transcription factor
- the size and shape of the melanosomes influence their light-scattering properties and thus the color appearance of the skin. For example, in black Africans, large spheroidal, isolated melanosomes are increasingly found, whereas in Caucasians, smaller, grouped melanosomes are found.
- UV radiation e.g., freckles, ephelides
- genetic predisposition e.g., skin malignancy in wound healing or scarring (post-inflammatory hyperpigmentation) or aging of the skin (e.g., lentigines seniles).
- emulsions This is generally understood to mean a heterogeneous system consisting of two liquids which are not miscible or have only limited miscibility, which are usually referred to as phases. One is in the form of droplets (dispere or inner phase), while the other liquid is a continuous forms a continuous (coherent or internal phase).
- Rarer forms of administration are multiple emulsions, ie those which in turn contain droplets of a further dispersed phase in the droplets of the dispersed (or discontinuous) phase, for example W / O / W emulsions and OW / O emulsions.
- Cosmetic preparations with 4-n-butylresorcinol are known, for example from EP 1 490 017.
- 4-n-butylresorcinol is also called rucinol or lucinol. It inhibits elanin production by inhibiting the enzyme necessary for melanin synthesis (melanogenesis), tyrosinase. It initially inhibits melanin production, then blocks the production of black melanin, which is responsible for the intense coloration of the pigment spots.
- 4-n-butylresorcinol is largely solubilized in the fatty phase. It was therefore surprising that disulfites, which are water-soluble but largely insoluble in fat, could lead to the stabilization of 4-n-butylresorcinol.
- Cosmetic or dermatological preparations according to the invention preferably contain from 0.001 to 10% by weight, particularly preferably from 0.01 to 1% by weight, of 4-n-butylresorcinol, based on the total composition of the preparations.
- a particularly preferred composition in the sense of the present invention is embodied by preparations containing 0.001-10% by weight, particularly preferably 0.01-5% by weight, very particularly preferably 0.05-1% by weight, of one or several disulfites.
- the disulphite (s ) are selected from the group of water-soluble disulphites, with sodium disulphite (Na 2 S 2 O 5 ) being the preferred one.
- the cosmetic and dermatological preparations are applied according to the invention in the usual manner for cosmetics on the skin and / or hair in sufficient quantity.
- cosmetic and dermatological preparations which are in the form of a sunscreen.
- these may additionally comprise at least one further UVA filter and / or at least one further UVB filter and / or at least one inorganic pigment, preferably an inorganic micropigment.
- the cosmetic and dermatological preparations according to the invention may contain cosmetic adjuvants such as are conventionally used in such preparations, for example preservatives, bactericides, perfumes, substances for preventing foaming, dyes, pigments which have a coloring effect, thickeners, moisturizing and / or moisturizing agents Substances, fats, oils, waxes or other common ingredients of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
- cosmetic adjuvants such as are conventionally used in such preparations, for example preservatives, bactericides, perfumes, substances for preventing foaming, dyes, pigments which have a coloring effect, thickeners, moisturizing and / or moisturizing agents.
- Substances, fats, oils, waxes or other common ingredients of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivative
- antioxidants which are suitable or customary for cosmetic and / or dermatological applications can be used as favorable antioxidants.
- the amount of the aforementioned antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30 wt .-%, particularly preferably 0.05 to 20 wt .-%, in particular 1-10 wt .-%, based on the total weight of Preparation.
- the cosmetic or dermatological preparation in the sense of the present invention is a solution or emulsion or dispersion, it is possible to use as solvent or as oil body:
- oils such as triglycerides of capric or caprylic acid, but preferably castor oil; Fats, waxes and other natural and synthetic fats, preferably esters of fatty acids with lower C-number alcohols, e.g. with isopropanol, propylene glycol or glycerol, or esters of fatty alcohols with alkanoic acids of low C number or with fatty acids;
- Alcohols, diols or polyols of low C number, and their ethers preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and analogous products.
- ethers preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and analogous products.
- mixtures of the abovementioned solvents are used.
- water can be another ingredient.
- the cosmetic or dermatological preparation in the sense of the present invention is a solution or emulsion or dispersion, it is possible to use as solvent:
- oils such as triglycerides of capric or caprylic acid, but preferably castor oil; Fats, waxes and other natural and synthetic fats, preferably esters of fatty acids with lower C-number alcohols, e.g. with isopropanol, propylene glycol or glycerol, or esters of fatty alcohols with alkanoic acids of low C number or with fatty acids;
- Alcohols, diols or polyols of low C number, and their ethers preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and analogous products ,
- mixtures of the abovementioned solvents are used.
- alcoholic solvents water can be another ingredient.
- Suitable propellants for sprayable from aerosol containers cosmetic and / or dermatological preparations in the context of the present invention the usual known volatile, liquefied propellants, such as hydrocarbons (propane, butane, isobutane) are suitable, which can be used alone or in mixture with each other. Also, compressed air is advantageous to use.
- hydrocarbons propane, butane, isobutane
- Cosmetic preparations in the sense of the present invention may also be present as gels which, in addition to an effective content of the active substance according to the invention and or other organic thickening agents, for example gum arabic, xanthan gum, sodium alginate, cellulose derivatives, preferably methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose or inorganic thickening agents, eg.
- organic thickening agents eg.
- aluminum silicates such as bentonites, or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate.
- the thickener is contained in the gel, for example, in an amount between 0.1 and 30 wt .-%, preferably between 0.5 and 15 wt .-%.
- the sunscreen formulations can advantageously contain further substances which absorb UV radiation in the UVB range, the total amount of the filter substances being e.g. 0.1 wt .-% to 30 wt .-%, preferably 0.5 to 10 wt .-%, in particular 1 to 6 wt .-%, based on the total weight of the preparations to provide cosmetic preparations, which protect the skin from the entire range of ultraviolet radiation. They can also serve as sunscreen.
- bi- or disulphites sodium bisulphite, sodium metasulphite, sodium disulphite
- cosmetic bases such as emulsions and hydrogels
- the preferred Na disulphite Na 2 S 2 O 5 according to the invention is present in aqueous solution as NaHSO 3 .
- the "discoloration” parameter is to be defined using a measurement method: A commercially available “Spectro-Pen” measures three values that span the so-called L * a * b color space and provide information about the brightness and the color space by comparing the determined values ,
- Each perceptible color in the color space is defined by the color locus with the coordinates ⁇ L * , a *, b * ⁇ on 3 axes.
- the values of the brightness are described by the AL value (endpoints: black and white, describes the gray tones) and the colors green and red are described by the a * value, the colors blue and yellow by the b * value.
- the L * a * b * color space is a measurement space in which all perceptible colors are contained.
- One of the most important features of the L * a * b * color model is its device independence, that is, the colors are defined independently of the nature of their generation and rendering technique.
- the thus standardized color space is as described equidistant and device-independent. Every perceptible color in the color space is defined by the color locus with the coordinates ⁇ L *, a *, b * ⁇ .
- the L * a * b * color space is described by a three-dimensional coordinate system.
- the a * axis describes the green or red portion of a color, with negative values for green and positive values for red.
- the b * axis describes the blue or yellow part of a color, with negative values for blue and positive values for yellow.
- the a * axis and b * axis scales include a number range of -150 to +100 and -100 to +150, despite the fact that there is no perceptible correspondence for some values.
- the L * axis is perpendicular to these planes and represents the brightness (luminance) of the colors with values from 0 to 100.
- Type no. LMG161 Exemplary example recipe for the measurement:
- the active ingredients were each stabilized (with sodium metabisulfite) and incorporated unstabilized.
- the formulations were stored under various standard conditions - eg 40 ° C, light, room temperature - and examined after 4 and 8 weeks of storage.
- PEG-40 Stearate 1, 00 1, 00 - -
- the sample to be measured is filled into a vial with a smooth bottom ("Wheaton liquid scintillation vials", glass, 20 ml) with a defined filling height (the samples to be compared should have the same filling level) held on the glass and it is calculated by the device, the average of the measured 5 individual measurements of the L * a * b * values.
- > 2 can be viewed in the sanctity value L * .
- Vitamin B3 (niacinamide) - 0.5 - -
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE200910048977 DE102009048977A1 (de) | 2009-10-09 | 2009-10-09 | Kosmetische oder dermatologische Zubereitungen mit Kombinationen aus 4-n-Butylresorcin und einem oder mehreren Sulfiten, insbesondere Hydrogensulfiten und/oder Disulfiten |
PCT/EP2010/004249 WO2011042075A2 (de) | 2009-10-09 | 2010-07-13 | Kosmetische oder dermatologische zubereitungen mit kombinationen aus 4-n-butylresorcin und einem oder mehreren sulfiten, insbesondere hydrogensulfiten und/oder disulfiten |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2485809A2 true EP2485809A2 (de) | 2012-08-15 |
Family
ID=43734637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10737499A Withdrawn EP2485809A2 (de) | 2009-10-09 | 2010-07-13 | Kosmetische oder dermatologische zubereitungen mit kombinationen aus 4-n-butylresorcin und einem oder mehreren sulfiten, insbesondere hydrogensulfiten und/oder disulfiten |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2485809A2 (de) |
CN (1) | CN102811771A (de) |
DE (1) | DE102009048977A1 (de) |
WO (1) | WO2011042075A2 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102012217894A1 (de) * | 2012-10-01 | 2014-04-03 | Beiersdorf Ag | Kosmetische Emulsion mit Polyacrylaten |
DE102012222445A1 (de) * | 2012-12-06 | 2014-06-26 | Beiersdorf Ag | Kosmetische oder dermatologische Zubereitungen mit Kombinationen aus4-n-Butylresorcin und einem oder mehreren nichtterpenoiden Parfumrohstoffen |
FR3113835B1 (fr) * | 2020-09-07 | 2023-12-01 | Oreal | Composition cosmétique procurant des sensations uniques |
US20210401702A1 (en) * | 2020-06-30 | 2021-12-30 | L'oreal | Cosmetic composition providing unique sensations |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2835522A1 (fr) * | 2002-02-06 | 2003-08-08 | Robert Vachy | Preparation pour composes sensibles a l'oxydation et son procede de fabrication |
US20030180234A1 (en) * | 2002-03-22 | 2003-09-25 | Unilever Home & Personal Care Usa, | Stabilization of resorcinol derivatives in cosmetic compositions |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2764189B1 (fr) * | 1997-06-09 | 1999-08-27 | Coletica | Utilisation de sulfites et metabisulfites, pour la fabrication de compositions cosmetiques ou pharmaceutiques, notamment en dermatologie, a effet inhibiteur de la melanogenese ou a activite depigmentante |
WO2002072039A2 (en) * | 2001-03-09 | 2002-09-19 | Pentapharm Ltd | Topical preparations and food preparations comprising a pyridoxine-alpha-d-glucose |
JP2003160461A (ja) * | 2001-11-21 | 2003-06-03 | Shiseido Co Ltd | 皮膚外用剤 |
US6869598B2 (en) | 2002-03-22 | 2005-03-22 | Unilever Home & Personal Care Usa Division Of Conopco, Inc. | Stabilization of sunscreens in cosmetic compositions |
JP2005179226A (ja) * | 2003-12-18 | 2005-07-07 | Shiseido Co Ltd | 柏子仁から美白成分を抽出する方法 |
JP2006124358A (ja) * | 2004-11-01 | 2006-05-18 | Shiseido Co Ltd | 4−アルキルレソルシノール誘導体及びこれを有効成分とする美白剤 |
US20090162305A1 (en) * | 2006-01-05 | 2009-06-25 | Symrise Gmbh & Co. Kg | Formulations of low oil content comprising diphenylmethane derivatives |
DE102007028508A1 (de) * | 2007-06-18 | 2008-04-03 | Henkel Kgaa | Stabilisierung von Deodorantien und Antitranspirantien |
-
2009
- 2009-10-09 DE DE200910048977 patent/DE102009048977A1/de not_active Withdrawn
-
2010
- 2010-07-13 EP EP10737499A patent/EP2485809A2/de not_active Withdrawn
- 2010-07-13 CN CN2010800454752A patent/CN102811771A/zh active Pending
- 2010-07-13 WO PCT/EP2010/004249 patent/WO2011042075A2/de active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2835522A1 (fr) * | 2002-02-06 | 2003-08-08 | Robert Vachy | Preparation pour composes sensibles a l'oxydation et son procede de fabrication |
US20030180234A1 (en) * | 2002-03-22 | 2003-09-25 | Unilever Home & Personal Care Usa, | Stabilization of resorcinol derivatives in cosmetic compositions |
Non-Patent Citations (1)
Title |
---|
See also references of WO2011042075A2 * |
Also Published As
Publication number | Publication date |
---|---|
DE102009048977A1 (de) | 2011-04-14 |
CN102811771A (zh) | 2012-12-05 |
WO2011042075A2 (de) | 2011-04-14 |
WO2011042075A3 (de) | 2013-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2549979B1 (de) | Kosmetische oder dermatologische zubereitungen mit einem gehalt an einem oder mehreren thiazolderivaten | |
DE69716189T3 (de) | Verwendung von Melatonin-Derivaten zur Hautdepigmentierung sowie diese enthaltende Präparate | |
CH697417B1 (de) | Mittel zur Behandlung der Hautalterung enthaltend Paeoniflorin. | |
EP2485809A2 (de) | Kosmetische oder dermatologische zubereitungen mit kombinationen aus 4-n-butylresorcin und einem oder mehreren sulfiten, insbesondere hydrogensulfiten und/oder disulfiten | |
DE19720339A1 (de) | Wirkstoffe und Zubereitungen für die Hautaufhellung und zur Verhinderung der Hautbräunung | |
WO2015135606A1 (de) | Kosmetische oder dermatologische zubereitungen mit einem gehalt an decalinderivaten und verwendung von decalinderivaten zur bräunung der haut | |
EP2928443B1 (de) | Kosmetische oder dermatologische zubereitungen mit kombinationen aus 4-n-butylresorcin und tetrahydro-4-methyl-2-(2-methylpropyl)-2h-pyran-4-ol | |
EP2957275B1 (de) | Kosmetische oder dermatologische zubereitungen mit kombinationen aus 4-n-butylresorcin und magnolienrindenextrakt sowie einem oder mehreren diolen | |
DE10352369A1 (de) | Verwendung von Licocalchon A oder eines Licocalchon A enthaltenden Extraktes aus Radix Glycyrrhizae inflatae gegen postinflammatorische Hyperpigmentierung | |
DE102009048976A1 (de) | Kosmetische oder dermatologische Zubereitung mit Kombinationen aus 4-n-Butylresorcin und einem oder mehreren Stearinsäureesten | |
EP2485707B1 (de) | Verwendung von 4-n-butylresorcin zur herstellung einer kosmetischen oder dermatologischen zubereitung zur prophylaxe oder behandlung von augenringen die durch eine gestörte durchblutung der haut im augenbereich hervorgerufen werden | |
WO2011042073A2 (de) | Kosmetische oder dermatologische zubereitungen mit kombinationen aus öllöslichen kosmetischen oder dermatologischen wirkstoffen und einem oder mehreren sulfiten (bisulfiten oder disulfiten) | |
DE10002725A1 (de) | Wirkstoffe und Zubereitungen für die Hautaufhellung und zur Verhinderung der Hautbräunung (skin whitening) | |
EP2485706B1 (de) | Verwendung von 4-n-butylresorcin zur verhinderung oder minderung der diffusion eines oder mehrerer bestandteile kosmetischer zubereitungen, insbesondere emulsionen in das die zubereitung umgebende behältermaterial | |
DE102008009799B4 (de) | Verwendung von 3-(4-Hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-propan-1-on gegen Hyperpigmentierung | |
EP2384738B1 (de) | Verwendung von Salicylsäureestern zur Geruchsmaskierung von Abbauprodukten des Harnstoffs | |
EP2969029B1 (de) | Verwendung kosmetisch oder dermatologisch unbedenklicher substituierter michael-akzeptoren zur verhinderung, verminderung oder prophylaxe der tyrosinaseaktivität der menschlichen haut und/oder deren aufhellung | |
WO2018137854A1 (de) | Wirkstoffkombinationen aus trans-4-t-butylcyclohexanol und einem oder mehreren alkylamidothiazolen sowie kosmetische oder dermatologische zubereitungen, diese wirkstoffkombinationen enthaltend | |
DE102006047156A1 (de) | Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an 2-Isopropyl-5-Methyl-Cyclohexancarbonyl-D-Alaninethylester und einem oder mehreren hautaufhellenden Wirkstoffen gegen unerwünschte Pigmentierung der Haut, insbesondere postinflammatorische Hyperpigmentierung | |
KR20170026733A (ko) | 피부 미백용 화장료 조성물 | |
WO2008040458A1 (de) | Kosmetische oder dermatologische zubereitungen mit einem gehalt an 2-isopropyl-5- methyl-cyclohexancarbonyl-d-alaninmethylester und einem oder mehreren hautaufhellenden wirkstoffen gegen unerwünschte pigmentierung der haut, insbesondere postinflammatorische hyperpigmentierung | |
DE102012214041A1 (de) | Verwendung von alpha-Bisabolol, Benzylalkohol, Benzoesäure, Phenoxetol und anderen Wirkstoffen zur Geruchsmaskierung von Abbauprodukten des Carnitins | |
DE102009007528A1 (de) | Wärmende kosmetische oder dermatologische Zubereitungen | |
DE102008009797A1 (de) | Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an 3-(4-Hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-propan-1-on und Ethylhexyl-2-cyano-3,3-diphenylacrylat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME RS |
|
DAX | Request for extension of the european patent (deleted) | ||
R17D | Deferred search report published (corrected) |
Effective date: 20130613 |
|
17P | Request for examination filed |
Effective date: 20131213 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: WOEHRMANN, MICHAEL Inventor name: AHLHEIT, SABRINA Inventor name: KOLBE, LUDGER Inventor name: SCHERNER, CATHRIN |
|
17Q | First examination report despatched |
Effective date: 20170308 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20190129 |